a major advance thanks to a blood test

Hormone -dependent breast cancer is the most common breast cancer – 80 % of diagnosed breast cancers. Similarly, He is also the one who presents the best prognosis.

However. Additionally, Similarly, at the metastatic stage – when cancer cells have remotely migrated from the initial cancer area – it becomes resistant to standard treatment, hormone therapy which blocks the activation of the estrogen receptor as it inhibits the proliferation of cells. Meanwhile,

This resistance occurs in almost 40 % of cases. Meanwhile, It is most often explained by mutations in the ESR1 estrogen receptor genes which lead to resistance to hormone therapy.

Liquid biopsy to identify the resistance mutations early – Major advance thanks blood test

These mutations can be detected months before reactivation of cancer thanks to a liquid biopsy. In addition, A blood test to identify circulating tumor DNA. Similarly, Early detecting it would then target the mutations responsible major advance thanks blood test for resistance thanks to the lamp. Furthermore, family of hormone therapy molecules, selective inhibitors of estrogen receptors. Family who recently enriched new more effective molecules including the Camizestrant (Astrazeneca).

A large international clinical trial of phase 3. the results of which were presented on Sunday 1^is June at theAmerican society of clinical oncology (ASCO) and published in The New england journal of Medicinemonitored 3,000 patients with hormone -dependent metastatic breast cancer. All followed the standard treatment. suffered every two to three months, a blood test aimed at detecting a resistant mutation.

A therapeutic change before relapse

The 315 patients who presented this mutation were divided into two groups: the first continued to receive standard treatment. the second received the Camizestrant combined with the cell proliferation inhibitor. Oral hormone therapy was changed from the first signs of genetic changes in the blood.

“Patients receiving Camizestrant saw their risk of cancer evolution decrease by major advance thanks blood test 56 %, pushing around 6 months on average until the first re-evolution. At 12 months old, the rate of unpaid survival was 60.7 % for patients who received Camizestrant against 33.4 % in others. At 24 months, progression -free survival reached 29.7 % against 5.4 % ”, described the Curie Institute, in a press release.

Another advantage. the quality of life was also improved: patients under standard treatment saw their quality of life decline from 6 months after the appearance of mutations, against 23 months on average in patients who have changed treatment.

A strategy applied to other cancers?

“Ten years will have passed between the development in the laboratory of a blood test detecting resistance changes. the results of the Serena-6 study. If the PADA-1 study. which we had conducted in France thanks to the Unicancer network, had established proof of concept, Serena-6 serious in marble that our strategy of interception major advance thanks blood test of resistance, thanks to regular non-invasive monitoring by blood test and a change of treatment, leads to a tangible benefit for the survival and quality of life of patients “, Enthuses Prof. François-Clément Bidard. medical oncologist at the Ihu Institute of Women’s Cancers of the Institut Curie, professor at the University of Versailles-Saint-Quentin and Co-Pilote of the Serena-6 study.

« These very positive results validate the potential of our interception approach by detecting mutations in circulating tumor DNA. Now. research and clinical prospects are fascinating, this strategy that can potentially exploor in other situations and types of cancers, and lead to the recording of new drugs. »»